Cancer Supportive Drug Care Market, By Therapeutic Class (G-CSFS (Granulocyte Colony Stimulating Factor), ESAS (Erythropoiesis-Stimulating Agents), Antiemetics, Bisphosphonates, Opioids, NSAIDS (Nonsteroidal Anti-Inflammatory Drug), and Other), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032

Report Code: PMI102419 | Publish Date: March 2024 | No. of Pages: 186

Global Cancer Supportive Care Market Companies

  • Novartis AG
  • F.Hoffmann
  • La-Roche Ltd.
  • Amgen, Inc.
  • Baxter International, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Acacia Pharma Ltd.
  • Merck and Co., Inc.
  • Helsinn Healthcare SA
  • Heron Therapeutics.

Recent News:

  • SOPHiA GENETICS, a cloud-native healthcare software provider, announced in February 2023 that Synergy Oncology, a division of Synergy Laboratories, a full-service diagnostic laboratory with headquarters in Mobile, Alabama, will utilize SOPHiA DDMTM to create a novel cancer profiling tool. The technology synergy Oncology and SOPHiA GENETICS combined will grow Synergy's oncology portfolio and advance the cancer market in the United States.
  • To enhance OncoPower's cancer care support, Mark Cuban Cost Plus Drug Company and OncoPower teamed up in January 2023 to bring medication adherence and cost savings to cancer patients. Introducing a Medication Savings Suite, which takes advantage of Cost Plus Drugs' competitive pricing on generic medication, allows OncoPower users to compare prices and order less expensive drugs.
  • Takeda and HUTCHMED, the pharmaceutical companies producing the medicine, have stated that the FDA granted a primary review for a New medicine Application (NDA), including fruquintinib, in June 2021 for patients with metastatic colorectal cancer who had received prior treatment.